Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review

  title={Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review},
  author={Nicholas Li-Xun Syn and Wei Peng Yong and Boon Cher Goh and Soo-Chin Lee},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  pages={911 - 922}
ABSTRACT Introduction: Tumour molecular profiling has been at the crossroads of large-scale integrative genomic studies and major clinical trials over the past 5 years and has provided roadmaps for better disease stratification and therapeutic management. Areas covered: We review the landscape of precision oncology trials in Asia, Europe and the United States, and emerging insights gained from recently reported studies such as the SHIVA and CUSTOM trials. Changes in the molecular portraits of… 
Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study
Next‐generation sequencing (NGS) and routine clinicopathological assays, such as immunohistochemistry, copy number analysis and in situ hybridization tests, were performed on tumor samples and actionable biomarker results were used to identify eligibility for early‐phase, biomarker‐driven clinical trials.
Extracellular Vesicles: A Novel Tool Facilitating Personalized Medicine and Pharmacogenomics in Oncology
Tumor EVs can promote the remodeling of the tumor microenvironment and pre-metastatic niche formation, and contribute to transfer of oncogenic potential or drug resistance during chemotherapy during chemotherapy, which makes them a promising source of minimally invasive biomarkers.
Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy
In this progress report, studies describing in vitro DSRTs on 2D and 3D cell models based on patient‐derived cells are reviewed and challenges and future steps needed for the adaptation of these systems in clinics are discussed.
Immunogenomics: using genomics to personalize cancer immunotherapy
The basis for including genomic data in immunotherapy regimens, the current progress in identifying biomarkers targetable by immune checkpoint blockade, and the application of these therapies in modern oncology programs are discussed.
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study.
Real-time targeted molecular profiling of patients with recurrent or advanced ovarian cancer was deemed feasible and useful in routine clinical practice and identified known genomic and methylation alterations of the different ovarian cancer subtypes.
Pharmacogenetics and Personalized Medicine
Despite the increasing complexity of pharmacogenetic analyses and their interpretation, some relationships between genetic biomarkers and treatment outcomes may be characterized by suboptimal values of sensitivity and specificity.
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial
This bench-to-bedside effort establishes a reasonable turnaround time for gene expression profiling and possible utility of genomic classifiers in gastric cancer treatment stratification.
Urinary exosomal shuttle RNA: Promising cancer diagnosis biomarkers of lower urinary tract
This review comprehensively summarizes state of the art approaches used in the discovery and validation of exosomal RNA biomarkers purified from the urine for lower urinary tract cancer.


The prognostic landscape of genes and infiltrating immune cells across human cancers
A pan-cancer resource and meta-analysis of expression signatures from ∼18,000 human tumors with overall survival outcomes across 39 malignancies is presented and it is found that expression of favorably prognostic genes, including KLRB1 (encoding CD161), largely reflect tumor-associated leukocytes.
Precision medicine for metastatic breast cancer—limitations and solutions
Limitations and solutions are discussed, which include scaling-up the number of patients screened for identifying a genomic alteration, the clustering of genomic alterations into pathways, and the development of personalized medicine trials.
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
It is possible to identify molecular targets in patients' tumors from nine different centers across the United States and in 27% of patients, the MP approach resulted in a longer PFS on an MP-suggested regimen than on the regimen on which the patient had just experienced progression.
Analysis of circulating tumor DNA to monitor metastatic breast cancer.
This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer.
Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream.
  • G. LymanH. Moses
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
The committee's recommendations presented and discussed here are fundamentally grounded in the understanding that, when properly validated and appropriately implemented, these assays and corresponding therapies hold considerable promise to enhance the quality of patient care and improve meaningful clinical outcomes.
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
This basket trial design was not feasible for many of the arms with rare mutations, but it allowed the study of the genetics of less common malignancies.
The BATTLE trial: personalizing therapy for lung cancer.
The BATTLE study is the first completed prospective, adaptively randomized study in heavily pretreated NSCLC patients that mandated tumor profiling with "real-time" biopsies, taking a substantial step toward realizing personalized lung cancer therapy by integrating real-time molecular laboratory findings.
Toward personalized treatment for gastroesophageal adenocarcinoma (GEC): Strategies to address tumor heterogeneity—PANGEA.
There is need for novel clinical trial designs/strategies implementing novel technologies to account for inter-patient molecular heterogeneity within GEC and within an individual through space and time - a hurdle to advancing GEC treatment.